Fatty liver (MASLD) is now the most common liver condition globally. Most people have no symptoms — but without monitoring, it can silently progress to cirrhosis and liver cancer.
Fatty liver disease (now called MASLD — Metabolic-Associated Steatotic Liver Disease) occurs when excess fat accumulates in liver cells. In India, 1 in 3 adults has fatty liver — most are unaware.
LFTs, CBC, fasting lipid profile, HbA1c, thyroid function, and metabolic assessment to establish disease context.
Non-invasive imaging to confirm hepatic steatosis, assess liver size, and detect early fibrosis or portal hypertension signs.
Measures liver stiffness (fibrosis stage) and CAP score (fat content) without biopsy. Available at Dhaara Liver Clinic.
Gold standard for staging MASH and fibrosis when non-invasive tests are inconclusive or when diagnosis changes management.
10% weight loss reduces liver fat by 50–80% and can reverse early MASH. Personalised diet and exercise programme with nutritionist collaboration.
Aggressive management of diabetes, hypertension, and dyslipidaemia. GLP-1 receptor agonists (semaglutide, liraglutide) are highly effective for MASLD with obesity.
Vitamin E (in non-diabetic MASH), pioglitazone (in diabetic MASH), and emerging approved agents (resmetirom/Rezdiffra) for fibrosis stage ≥ F2.
Cirrhosis due to MASLD carries significant HCC risk. Regular ultrasound + AFP monitoring to detect liver cancer at an early, treatable stage.
